[
  {
    "ts": null,
    "headline": "Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else",
    "summary": "Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.",
    "url": "https://finnhub.io/api/news?id=23bb3126f4a6e5992ab21b93f22f0c851993cc7ea1edf9481d5f2135351402c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734535886,
      "headline": "Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else",
      "id": 132040274,
      "image": "https://media.zenfs.com/en/ibd.com/3a897c85d50513809da70438e2285a69",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.",
      "url": "https://finnhub.io/api/news?id=23bb3126f4a6e5992ab21b93f22f0c851993cc7ea1edf9481d5f2135351402c0"
    }
  },
  {
    "ts": null,
    "headline": "What's Going On With Viking Therapeutics Stock On Wednesday?",
    "summary": "On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments",
    "url": "https://finnhub.io/api/news?id=a5d4170dafb269cd085c8679b73a5eb157a274df6e4f310515dc8e17c7f7cc28",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734545559,
      "headline": "What's Going On With Viking Therapeutics Stock On Wednesday?",
      "id": 132043094,
      "image": "https://media.zenfs.com/en/Benzinga/a86733448104c6ba0b9cb63af0c54517",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "On Wednesday, Merck & Co Inc (NYSE:MRK) and Hansoh Pharma, a Chinese biopharmaceutical company, entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist. Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture, and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments",
      "url": "https://finnhub.io/api/news?id=a5d4170dafb269cd085c8679b73a5eb157a274df6e4f310515dc8e17c7f7cc28"
    }
  },
  {
    "ts": null,
    "headline": "Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute",
    "summary": "Yahoo Finance host Rachelle Akuffo eyes three of this morning's biggest market stories in today's Market Minute. Tesla (TSLA) CEO Elon Musk's net worth hits a record-breaking $500 billion as the EV maker's stock climbed following the 2024 election results. Netflix (NFLX) has been fined $4.8 million by Dutch regulators over the streaming platform's mishandling of consumer data. Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
    "url": "https://finnhub.io/api/news?id=3b00b112a67af92937bfadbcb9dfa8ab03ada92b8bd5e0d448274c02419ceed2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734540767,
      "headline": "Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute",
      "id": 132041094,
      "image": "https://s.yimg.com/ny/api/res/1.2/JTg8auIxYjg.wltbpCsnvw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzU-/https://s.yimg.com/os/creatr-uploaded-images/2024-12/707105a0-bd60-11ef-adff-03e4809bcc22",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Yahoo Finance host Rachelle Akuffo eyes three of this morning's biggest market stories in today's Market Minute. Tesla (TSLA) CEO Elon Musk's net worth hits a record-breaking $500 billion as the EV maker's stock climbed following the 2024 election results. Netflix (NFLX) has been fined $4.8 million by Dutch regulators over the streaming platform's mishandling of consumer data. Merck (MRK) signed a licensing agreement with Chinese biotech company Hansoh Pharma (3692.HK) for its oral GLP-1 weigh-loss drug is valued as high as $2 billion. To watch more expert insights and analysis on the latest market action, check out more Wealth here. This post was written by Luke Carberry Mogan.",
      "url": "https://finnhub.io/api/news?id=3b00b112a67af92937bfadbcb9dfa8ab03ada92b8bd5e0d448274c02419ceed2"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=54fbb65eec075b262fd9c3d737ecc6c0da845cdc18dd16acca91fb77a9a3ee9f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734539700,
      "headline": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "id": 132065114,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck & Co. Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=54fbb65eec075b262fd9c3d737ecc6c0da845cdc18dd16acca91fb77a9a3ee9f"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Fed Cuts Rates",
    "summary": "GIS reports results; Nvidia's GB200 AI and HPC servers to reach mass production in 2025; Merck partners with Hansoh on GLP-1 receptor agonist for weight loss. Click for more.",
    "url": "https://finnhub.io/api/news?id=16e4f928f1ab7a13e5a3274b2c2e83f15f9e32b701b7a5b865ad6f33e7ce3408",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734535896,
      "headline": "Wall Street Lunch: Fed Cuts Rates",
      "id": 132041293,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2182769735/image_2182769735.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "GIS reports results; Nvidia's GB200 AI and HPC servers to reach mass production in 2025; Merck partners with Hansoh on GLP-1 receptor agonist for weight loss. Click for more.",
      "url": "https://finnhub.io/api/news?id=16e4f928f1ab7a13e5a3274b2c2e83f15f9e32b701b7a5b865ad6f33e7ce3408"
    }
  },
  {
    "ts": null,
    "headline": "Merck to End Development of Two Cancer Candidates: Time to Sell?",
    "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.",
    "url": "https://finnhub.io/api/news?id=d54c3e6b5bdce5350fc3746f1778e1ade14e2263d9c848c5feaf2039c8067d32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734533340,
      "headline": "Merck to End Development of Two Cancer Candidates: Time to Sell?",
      "id": 132043097,
      "image": "https://media.zenfs.com/en/zacks.com/cb27584804ea583a87d27499a6976ec2",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.",
      "url": "https://finnhub.io/api/news?id=d54c3e6b5bdce5350fc3746f1778e1ade14e2263d9c848c5feaf2039c8067d32"
    }
  },
  {
    "ts": null,
    "headline": "Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy",
    "summary": "Merck has partnered with Hansoh, a Chinese biopharmaceutical company, for a global licensing deal to develop an oral GLP-1 receptor agonist for the treatment of conditions related to metabolism and obesity. With this development, the New Jersey-based pharma company has now joined a race that has so far been dominated by the likes of Eli […]",
    "url": "https://finnhub.io/api/news?id=f6e95f83a505a0222825e185e26136f6a8a891b2602f75a1b533cf7126e6a236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734531259,
      "headline": "Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy",
      "id": 132043098,
      "image": "https://media.zenfs.com/en/insidermonkey.com/a5e685e9d707dd21a76d4183bd132af0",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck has partnered with Hansoh, a Chinese biopharmaceutical company, for a global licensing deal to develop an oral GLP-1 receptor agonist for the treatment of conditions related to metabolism and obesity. With this development, the New Jersey-based pharma company has now joined a race that has so far been dominated by the likes of Eli […]",
      "url": "https://finnhub.io/api/news?id=f6e95f83a505a0222825e185e26136f6a8a891b2602f75a1b533cf7126e6a236"
    }
  },
  {
    "ts": null,
    "headline": "Merck moves into obesity with deal for Hansoh’s GLP-1 pill",
    "summary": "News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.",
    "url": "https://finnhub.io/api/news?id=9ff2b7f90279bb5068a79a2f950220d4c8212b342c4149c58e13f2f79e0e955b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734523174,
      "headline": "Merck moves into obesity with deal for Hansoh’s GLP-1 pill",
      "id": 132043100,
      "image": "https://imgproxy.divecdn.com/L7a9BLKRniIGxLH4q8G9bsI_Rl6w7sscEA3nniUJesQ/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xODI5MzE1ODcuanBn.webp",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.",
      "url": "https://finnhub.io/api/news?id=9ff2b7f90279bb5068a79a2f950220d4c8212b342c4149c58e13f2f79e0e955b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist",
    "summary": "RAHWAY, N.J., December 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.",
    "url": "https://finnhub.io/api/news?id=5748d04c8760a792adf0cfb2a2d27878b91b992ae73ad7c7984ec392aadef48b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734522300,
      "headline": "Merck Enters into Exclusive Global License Agreement with Hansoh Pharma for Investigational Oral GLP-1 Receptor Agonist",
      "id": 132043101,
      "image": "https://media.zenfs.com/en/business-wire.com/1a6428d198c36e9f22b6a800d5d6195b",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., December 18, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Hansoh Pharma, a Chinese biopharmaceutical company, today announced that they have entered into an exclusive global license agreement for HS-10535, an investigational preclinical oral small molecule GLP-1 receptor agonist.",
      "url": "https://finnhub.io/api/news?id=5748d04c8760a792adf0cfb2a2d27878b91b992ae73ad7c7984ec392aadef48b"
    }
  },
  {
    "ts": null,
    "headline": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
    "summary": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
    "url": "https://finnhub.io/api/news?id=cdae4bed95768fdc2b341344e3cc0efbdef70792cd68f0f4171f50453b2742c9",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734517500,
      "headline": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
      "id": 132064404,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Merck Licenses a Weight-Loss Pill. It’s Bad News for Obesity Biotechs.",
      "url": "https://finnhub.io/api/news?id=cdae4bed95768fdc2b341344e3cc0efbdef70792cd68f0f4171f50453b2742c9"
    }
  },
  {
    "ts": null,
    "headline": "Merck: agreement with China's Hansoh Pharma on GLP-1",
    "summary": "Merck announced on Wednesday the signature of a worldwide licensing agreement with Hansoh Pharma, with the aim of developing the experimental GLP-1 tablet developed by the Chinese pharmaceutical...",
    "url": "https://finnhub.io/api/news?id=90ccdf196c10b5b65874ef6e2b7603689d03c991cdcb7bc281c136973387966c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734509294,
      "headline": "Merck: agreement with China's Hansoh Pharma on GLP-1",
      "id": 132038471,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "Merck announced on Wednesday the signature of a worldwide licensing agreement with Hansoh Pharma, with the aim of developing the experimental GLP-1 tablet developed by the Chinese pharmaceutical...",
      "url": "https://finnhub.io/api/news?id=90ccdf196c10b5b65874ef6e2b7603689d03c991cdcb7bc281c136973387966c"
    }
  },
  {
    "ts": null,
    "headline": "Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion",
    "summary": "By Colin Kellaher Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on...",
    "url": "https://finnhub.io/api/news?id=f63e18d144f8893a3abcaf0b8c33e373d22b909cb71eaa5f84dbf75666ffd32f",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734507628,
      "headline": "Merck, Hansoh Pharma in Obesity Pill License Potentially Worth More Than $2 Billion",
      "id": 132038280,
      "image": "",
      "related": "MRK",
      "source": "Finnhub",
      "summary": "By Colin Kellaher Merck & Co. is licensing a potential oral obesity drug from Hansoh Pharma in a deal potentially worth more than $2 billion to the Chinese biopharmaceutical company. Merck on...",
      "url": "https://finnhub.io/api/news?id=f63e18d144f8893a3abcaf0b8c33e373d22b909cb71eaa5f84dbf75666ffd32f"
    }
  }
]